Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 207

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial

Open access
Fizazi, Karim, Pagliaro, Lance, Laplanche, Agnes, Fléchon, Aude, Mardiak, Josef, Geoffrois, Lionnel, Kerbrat, Pierre, Chevreau, Christine, Delva, Remy, Rolland, Frederic, Theodore, Christine, Roubaud, Guilhem, Gravis, Gwenaëlle, Eymard, Jean-Christophe, Malhaire, Jean-Pierre, Linassier, Claude, Habibian, Muriel, Martin, Anne-Laure, Journeau, Florence, Reckova, Maria, Logothetis, Christopher, Culine, Stephane · 2014 · The Lancet Oncology

Abstract

Background Poor-prognosis germ-cell tumours (GCT) are associated with only a 50% cure rate. Our hypothesis was that treatment intensification based on an early tumour marker decline will improve progression-free survival (PFS). Methods In this phase III, multicentre, international trial (NCT00104676 ; EU-20502), after patients with poor-prognosis GCT defined according to the International Germ-Cell Cancer Consensus Group (IGCCCG) had received one cycle of cisplatin (20 mg/m2/day × 5 days), etoposide (100 mg/m2/day × 5 days), and bleomycin (30 mg/week) (BEP), AFP and hCG were assessed between day 18 and 21: 1) patients with a favourable decline continued BEP (Fav-BEP); 2) patients with an unfavourable decline were randomised to receive either BEP (Unfav-BEP) or a dose-dense regimen (Unfav-dose-dense), consisting of paclitaxel (175 mg/ m2 day 1)-BEP plus oxaliplatin (130 mg/ m2 day 10) (2 cycles), followed by cisplatin (100 mg/ m2 day 1), ifosfamide (2 g/ m2 on days 10, 12, 14 + mesna), and bleomycin (25 units/day, by continuous infusion × 5 days on day 10 to 14) (2 cycles), with G-CSF support. Centrally blocked randomisation stratified by centre was used. The primary endpoint was PFS and the efficacy analysis was conducted on an intention-to-treat basis i.e. it included all randomised patients. The planned trial accrual was completed in May 2012 and follow-up is ongoing. Results 263 patients were enrolled and 203 had an unfavourable tumour marker decline (randomised: 105 Unfav-dose-dense arm, 98 Unfav-BEP arm). The 3-year PFS rate was 59% [95% Confidence Interval (CI): 49–68] in the Unfav-dose-dense arm versus 48% [95% CI: 38–59] in the Unfav-BEP arm (p=0.05; HR: 0.66 [95% CI: 0.44–1.00]). The 3-year PFS rate was 70% [95% CI: 57%–81%] for patients in the Fav-BEP arm (p=0.01 for PFS compared with the Unfav-BEP arm). More grade 3–4 neurotoxicity (7 [7%] vs 1 [1%]) and greater haematotoxicity occurred in the dose-dense arm, with no excess febrile neutropenia (18 [17%] vs 18 [18%]) or toxic deaths (1 each arm). Salvage high-dose chemotherapy + a stem-cell transplant were required in 6 [6%] in the Unfav-dose-dense arm and 16 [16%] patients in the Unfav-BEP arm (p=0.015). Conclusion Personalising treatment with chemotherapy intensification reduces the risk of progression or death in patients with poor-prognosis GCT and an unfavourable tumour marker decline.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(14)70490-5

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 207

Metadata

Authors
Fizazi, K., Pagliaro, L., Laplanche, A., Fléchon, A., Mardiak, J., Geoffrois, L., Kerbrat, P., Chevreau, C., Delva, R., Rolland, F., Theodore, C., Roubaud, G., Gravis, G., Eymard, J.-C., Malhaire, J.-P., Linassier, C., Habibian, M., Martin, A.-L., Journeau, F., Reckova, M., Logothetis, C., & Culine, S.
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2014-12
Volume
15
Issue
13
Pages
1442-1450
ISSN
1470-2045 (ISSN-L)
OpenAlex
W2073794968
Cited by
207
References
1
FWCI
19.12
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial. https://app.cochat.ai/papers/10.1016/s1470-2045(14)70490-5
The paper
Fizazi, K., Pagliaro, L., Laplanche, A., Fléchon, A., Mardiak, J., Geoffrois, L., Kerbrat, P., Chevreau, C., Delva, R., Rolland, F., Theodore, C., Roubaud, G., Gravis, G., Eymard, J.-C., Malhaire, J.-P., Linassier, C., Habibian, M., Martin, A.-L., Journeau, F., . . . Culine, S. (2014). Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(14)70490-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.